AUSTRALIA – Australian biotech giant CSL announced that the regulatory review of its US$11.7 billion acquisition of Switzerland’s Vifor Pharma been postponed as antitrust investigations continue. The acquisition will take…
Read MoreRegulatory approvals delay CSL’s US$11.7 billion takeover of Vifor Pharma
